1. Switzerland Stocks

  2. •

    Finance

  3. •

    Financial conglomerates
BB Biotech AG

BB Biotech AG

49.85
CHF
-0.55
(-1.09%)
14.55EPS
3.32P/E
2.66BMarket Cap
Oct 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
82.3
130.35
11.8
-14.41
12.52
-8.41
12.37
12.62
-7.16
-6.38
-3.64
1.5
10.7
15
Basic EPS, GAAP
81.77
129.8
11.69
-14.51
12.42
-8.51
12.23
12.48
-7.31
-6.5
-3.77
1.38
10.54
14.55
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4.48
7.01
2.33
2.9
2.75
3.3
3.05
3.4
3.6
3.86
2.85
2
1.8
2.25
Book Value per Share
31.05
61.91
71.43
54.22
63.88
52.07
61.25
70.17
59.38
48.98
42.36
41.75
50.39
55.93
Tangible Book Value per Share
31.05
61.91
71.43
54.22
63.88
52.07
61.25
70.17
59.38
48.98
42.36
41.75
50.39
55.93
Basic Weighted Avg Shares
11
11
56
55
55
55
55
55
55
55
55
55
55
55
Sales/Revenue/Turnover
938
1,476
659
-796
693
-466
685
699
-396
-351
-200
82
587
826
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
932
1,470
653
-802
688
-471
677
691
-405
-358
-207
76
578
801
Effective Tax Rate (%)
0.01
0.01
0.01
- -
0.01
- -
0.01
0.01
- -
- -
- -
0.07
0.01
0.01
Profit Margin (%)
99.35
99.58
99.03
100.71
99.2
101.2
98.86
98.85
102.17
101.87
103.53
92.2
98.49
97.04
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
90
30
160
205
95
185
150
63
355
363
305
118
- -
- -
Total Equity
2,119
3,493
3,978
3,003
3,539
2,885
3,393
3,888
3,283
2,686
2,323
2,286
2,779
3,084
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
52.09
51.3
17.04
- -
20.1
- -
20.49
18.45
- -
- -
- -
3.02
22.31
31.86
Return on Common Equity (%)
55.58
52.4
17.48
-22.98
21.02
-14.68
21.58
18.99
-11.29
-11.99
-8.25
3.29
22.83
31.86

Capital Structure

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
55
55
55
Market Capitalization
2,490
2,367
2,664

Working Capital

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
98
355
204
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.02%
-5.46%
21.54%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-50.63%
62.51%
661.71%
Sales/Revenue/Turnover
-55.95%
52.13%
613.11%
Total Cash Common Dividend
-1.18%
-10.82%
-10.21%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
262
-79
-150
61
82
2025
-239
-94
- -
475
587
2026
-17
462
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.75
-1.6
-2.87
1.09
1.38
2025
-4.4
-1.83
- -
8.55
10.54
2026
-0.39
8.18
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
- -
- -
- -
2
2025
1.8
- -
- -
- -
1.8
2026
2.25
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Daniel Koller
Full Time Employees
73
Sector
Finance
Industry
Financial conglomerates
Address
Seestrasse 16 Schaffhausen Switzerland CH-8700
IPO Date
Nov 8, 2006
Website
bbbiotech.com
Similar Companies
Strategy Inc (NASDAQ:MSTR)
BitMine Immersion Technologies, Inc. (NYSE:BMNR)
Strive, Inc. (NASDAQ:ASST)
Hyperliquid Strategies Inc (NASDAQ:PURR)
Stablecoin Development Corporation (AMEX:SDEV)
Jio Financial Services Limited (NSE:JIOFIN)
Business
BB Biotech AG BB Biotech AG is a Swiss investment company that invests in publicly listed biotechnology firms developing and commercializing innovative drugs and therapies addressing unmet medical needs in oncology, neurological disorders, metabolic and cardiovascular diseases, infectious diseases, and autoimmune conditions; its portfolio, comprising 20 to 35 companies primarily in the United States and Western Europe, includes key holdings such as Argenx SE, Incyte, Relay Therapeutics, MacroGenics, Scholar Rock, Rivus Pharmaceuticals, Edgewise Therapeutics, Immunocore, Biohaven, and Avidity Biosciences, among others focused on cell, gene, and RNA-based technologies. Founded in 1993 and headquartered in Schaffhausen, Switzerland, BB Biotech AG operates globally with a focus on small- to mid-cap biotech entities aligned with the UN Sustainable Development Goal for good health and well-being, and its shares trade on the SIX Swiss Exchange and Frankfurt Stock Exchange. Recent developments include four major portfolio company acquisitions in 2025—Avidity Biosciences by Novartis for USD 12 billion, Intra-Cellular Therapies by Johnson & Johnson for USD 14.6 billion, Blueprint Medicines by Sanofi for up to USD 9.5 billion, and Akero Therapeutics by Novo Nordisk for up to USD 5.2 billion—alongside a new investment in Avidity Biosciences, portfolio reallocation toward high-potential assets like Ionis Pharmaceuticals and Alnylam Pharmaceuticals, and inclusion in the SPI ESG Index.